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Mijomir Pelemiš1, Goran Stevanović1*, Lidija Lavadinović1, Snežana Matić2, Ivana Milošević1, Miloš Korać1,
Svetislav Pelemiš3, Milan Nedeljković2 and Milica Prostran4Abstract: Disseminated fungal infections are still rare conditions, mostly caused by Candida spp. during
immunosuppression. Infection of immunocompetent individuals is uncommon. Endocarditis is a rare manifestation
during candidaemia, mostly in patients with prosthetic valves. Affection of previously unaltered valves is
uncommon.
Case presentation: We presented a case of a young, previously healthy female patient with endocarditis, caused
by Candida parapsilosis. The initial symptom, fever, was present four months before hospital admittance. She was
febrile without other symptoms and during observation in a local hospital. After her condition deteriorated, she
was transferred to the Institute for infectious and tropical diseases, Belgrade. Clinical findings on admission include
petechial skin rash and moderate hepatosplenomegaly. Newly developed systolic murmur was noted, and Candida
parapsilosis was isolated in multiple blood cultures. Echocardiography revealed 15 × 14 mm vegetations on the
right aortic vellum.
She was treated with antifungal drugs (fluconasole, liposomal amphotericin B), and the affected valve was
successfully replaced. The same strain of Candida parapsilosis was isolated from the intraoperative material of the
valve.
There were no markers of immunosuppression or other conditions which could affect the immune system.
Conclusion: After a prolonged period of treatment she was successfully cured, and she received a long-term
intermittent suppressive fluconasole therapy for the time being.
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Although disseminated fungal infections are more com-
mon today than before, they still remain rare conditions,
mostly caused by Candida spp. Candida parapsilosis
and Candida tropicalis are the most common causes in
Europe [1,2]. Risk factors include immunosuppression
(HIV, neutropenia, transplants, solid tumors), but infec-
tion of immunocompetent individuals is uncommon
[1,3]. Candidaemia has a significant mortality rate, up to
44% [1,2].
Endocarditis is present in 5-25% of patients with
candidaemia, mostly in patients with prosthetic valves
[4,5]. Affection of previously unaltered heart valves is* Correspondence: goran_drste@yahoo.com
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reproduction in any medium, provided the oruncommon. During the past 20 years, there have been
only three cases reported in Sweden [4]. Other authors
also refer to Candida endocarditis as an extremely rare oc-
currence in patients with normal native cardiac valves [6,7].Case presentation
We will present a case report of a previously healthy
twenty-three year old Caucasian female patient, from a
higher social-culture level, living in Belgrade suburbs.
She had a negative history data to preexisting diseases,
drug use or any underlining conditions.
First symptom-fever, presented four months before
hospital admittance, was treated with third generation
cephalosporin (ceftriaxone 2,0 gr daily i.v.) and resolved
within 5 days. During the next month she was febrile
without other symptoms. During that time the patient
was observed in a local hospital, until her condition
deteriorated - with anemia, leucopenia and petechiall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Infectious and Tropical Diseases, Belgrade, Clinical Centre
of Serbia. Clinical findings on admission included dis-
creet petechial skin rash, moderate hepatosplenomegaly,
whereas other systems were unaffected, including normal
heart sounds. Laboratory tests showed moderate elevation
of erythrocyte sedimentation rate, intermediary anemia
and leucopenia, with elevated C-reactive protein. (Table 1)
Candida parapsilosis- sensitive to all systemic antifungal
drugs was isolated in multiple blood cultures. The initial
treatment included IV fluconazole 200 mg/12 h. During
the third day of therapy, a newly developed systolic
murmur was noted, presenting an indication for echocar-
diography. The patient was afebrile starting from that
moment.
Echocardiography revealed 15 × 14 mm vegetations on
the right aortic vellum. (Figure 1) As Candida endocarditis
usually appears in immunosuppressive patients as well as
in patients with prosthetic valves, extensive clinical inves-
tigation was performed, to uncover any possible cause of
immunosuppression. During a four-week period, all
possible infectious agents were tested, including HIV,
HBV, HCV, EBV, Leischmania and tuberculosis. Normal
absolute count and ratio of CD4, CD2, CD3 and CD8
lymphocytes was noted, as well as normal concentration
of immunoglobulines and sufficient immunological
functions. There were no markers of autoimmune diseases
which could affect the immune system. Hematological in-
vestigation was performed, as well as abdominal and chest
CT, so the possible presence of solid tumors was excluded.
A "10-panel urine screen" drug test was negative. During
investigation, the patient was treated with fluconazole
(200 mg/12 h, i.v.). Control echocardiography showed
progressive enlargement of vegetations, spreading to the
other vellum, so the treatment was continued with
liposomal amphotericin B intravenously, 50 mg daily.
Since the transoesophageal echocardiography showed that
after two weeks of new treatment there were twoTable 1 Laboratory results during course of illness, and follow
Analysis* Admission day Day 15 Day 30 (preoperatively) Day
SE (mm/hour) 54 50 48
HgB (gr/l) 72 105 126
Er x1012/l 2,71 3,21 3,66
Le x109/l 3,7 3,1 4,0
Tr x109/l 218 317 298
fibrinogen (gr/l) 2,2 4,1 4,4
CRP (mg/l) 38 22 28
PT (sec) 14,5 13,2 12,9
Legend:
*SE- erythrocytes sedimentation rate during first hour, HgB – hemoglobin, Er – ery
PT – prothrombine time.additional vegetations affecting vellums (17 × 6 mm and
12 × 3 mm), it was necessary to replace the affected heart
valve. Control blood cultures, repeated daily from the fifth
day of hospitalization (patient was afebrile), were sterile.
Preoperatively, patient was treated with fluconazole for
38 days, and liposomal amphotericin B for 15 days. The
affected valve (Figure 2) was successfully replaced, and the
same strain of Candida parapsilosis was isolated from
intraoperative material of the valve.
Further conservative antifungal therapy was administered
after operation, until laboratory findings were normalized,
five months later. During this period the patient was
treated with liposomal amphotericin B for 36 days, IV in
the daily dose of 50 mg. For the rest of the period she was
treated with fluconazole IV 200 mg in the dose intervals
of 12 hours (approximately four months). During the
whole period, no side-effects were observed.
During the 3 year follow-up, there were no other
pathological developments, and the patient has been
physically active and working.Discussion
This report presents a rare disease progress in a young
and previously healthy person, without any predisposing
conditions - no immunodeficiency or previous valve defect
[4-6]. In spite of intensive systemic antifungal therapy,
which is recommended [2,4,5] there was no improvement,
so the operative valve replacement was necessary, which
has also been reported in other cases [4-7].
After the patient was discharged from the hospital, she
received a long-term intermittent suppressive fluconasole
therapy. There is some difference in opinion concerning
the time length of this therapy, including possibility of
life-long treatment [5,8,9]. During the three year follow-up,
our patient has been taking 200 mg of fluconasole twice a
week with complete recovery and no other physical
complaints.-up









throcytes, Le – leucocytes, Tr – thrombocytes, CRP – C-reactive protein,
Figure 1 Transthoracal echocardiografy in longitudinal and apical 4 chamber view vegetations on the aortic valves.
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Figure 2 Intraoperaive vegetation findings - aortic valve.
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Although rare, Candida endocarditis in previously healthy
patients, with no clear risk factors, is possible. During
blood cultivation, one should always look for fungus.
Candida endocarditis therapy is a combination of
antifungal drugs and surgery, and the use of drugs is long-
lasting.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
PM was the primary treating physician and is responsible for the treatment;
SG participated in the treatment of patients and manuscript preparation; LL
participated in the treatment of patients and manuscript preparation; MS
was the main treating cardiologist who was constantly monitoring the
patient; MI assisted in the treatment and monitoring of the patient and
helped to draft the manuscript; KM assisted in the treatment and monitoring
of the patient and helped to draft the manuscript; PS assisted in the
treatment and monitoring of the patient and helped to draft manuscript;
NM was the chief cardiologist responsible for echocardiogaphy and
preoperative preparation; PM was the clinical pharmacologist responsible for
the selection of antifungal drugs and their combination, as well as for the
monitoring of adverse effects. All authors read and approved the final form
manuscript.Acknowledgement
The Authors wish to acknowledge Milica Jovanovic MD, PhD, microbiologist,
who did an excellent job of identifying the causative agent.
Author details
1Clinic for Infectious and Tropical Diseases, Clinical Center of Serbia, Faculty
of Medicine, University of Belgrade, Bulevar oslobodjenja 16, 11000, Belgrade,
Serbia. 2Clinic for Cardiology, Clinical Center of Serbia, Dr Koste Todorovica 8,
11000, Belgrade, Serbia. 3Clinic for Otorhinolaringology, Clinical Center of
Serbia, Pasterova 2, 11000, Belgrade, Serbia. 4Department of Pharmacology,
Clinical Pharmacology and Toxicology, Faculty of Medicine, University of
Belgrade, 11000, Belgrade, Serbia.
Received: 14 November 2012 Accepted: 19 February 2013
Published: 22 February 2013
References
1. Marchetti O, Bille J, Fluckiger U, Eggiman P, Ruef C, Garbino J, Calandra T,
Glausser MP, Tauber MG, Pittet D: Epidemiology of candidemia in Swiss
tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004,
38:311–320.
2. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, Messer SA,
and SENTRY Participant Group: International surveillance of bloodstream
infections due to Candida species: frequency of occurrence and in vitro
susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates
collected from 1997 through 1999 in the SENTRY Antimicrobial
Surveillance Program. J Clin Microbiol 2001, 39:3254–3259.
3. Almirante B, Rodríguez D, Park BJ, et al: Epidemiology and Predictors of
Mortality in Cases of Candida Bloodstream Infection: Results from
Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003.
J Clin Microbiol 2005, 43(4):1829–1835.
4. Hogevik H, Alestig K: Fungal endocarditis – a report on seven cases and a
brief review. Infection 1996, 24:17–21.
5. Branco L, Pitta ML, Bernardes L, et al: A review of infectious endocarditis
due to Candida [Abstract]. Rev Port Cardiol 1997, 16:967–974.
6. Gullu AU, Akcar M, Arnaz A, et al: Candida parapsilosis tricuspid native
valve endocarditis: 3-year follow-up after surgical treatment.
Interact Cardiovasc Thorac Surg 2008, 7:513–514.
Pelemiš et al. Journal of Cardiothoracic Surgery 2013, 8:29 Page 5 of 5
http://www.cardiothoracicsurgery.org/content/8/1/297. Kan CD, Luo CY, Lin PY, et al: Native-valve endocarditis due to Candida
parapsilosis. Interact Cardiovasc Thorac Surg 2002, 1:66–68.
8. Zedtwitz-Liebenstein K, Gabriel H, Willinger B, et al: Prosthetic valve
endocarditis due to Candida tropicalis complicated by multiple
pseudoaneurysms. Infection 2001, 29:177–179.
9. Chim CS, Ho PL, Yuen ST, Yuen KY: Fungal endocarditis in bone marrow
transplantation: case report and review of literature. J Infect 1998,
37:287–291.
doi:10.1186/1749-8090-8-29
Cite this article as: Pelemiš et al.: A rare case of Candida parapsilosis
endocarditis in a young healthy woman – case report. Journal of
Cardiothoracic Surgery 2013 8:29.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
